AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$BBNX

Russell Steven Jon sold $53K of BBNX

Russell Steven Jon (Chief Medical Officer) sold 4,222 shares of Beta Bionics, Inc. (BBNX) at $12.61 on 2026-06-02.

Original reporting
SEC EDGAR · Russell Steven Jon
Published Jun 3, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Bearish
medium confidence
Mentioned
$BBNX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXBearishLow
01

Why it matters

This adds a new datapoint on insider behavior but does not introduce new clinical, regulatory, or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article doesn’t specify motives, whether proceeds were planned, or whether other insiders simultaneously bought/sold.

Relevance 6/10Novelty 3/10Timing: Filed today; sale occurred on 2026-06-02.

Background

The article is an SEC Form 4 insider transaction disclosure for Beta Bionics, Inc.

Company-level read

Ticker impact

$BBNXBearishMedium confidence
Context

Beta Bionics’ Chief Medical Officer sold 4,222 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low-to-mild near-term downside bias; impact likely limited unless accompanied by other negative company news.

Evidence & confidence

The filing provides a transaction datapoint (size/value and date) but no new operational or clinical catalyst; also no 10b5-1 plan is indicated.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Officer sales can be routine for diversification/tax and do not necessarily reflect negative expectations.

Key entities

  • issuer
    Beta Bionics, Inc.

    Subject of the SEC Form 4 insider transaction; Chief Medical Officer sold shares.

  • insider
    Russell Steven Jon

    Chief Medical Officer who reported the open-market sale.

Read at source← All news

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min